Why Is Tyenne So Hard to Find? [Explained for 2026]

If your doctor just prescribed Tyenne (tocilizumab-aazg) and you're having trouble getting it, you're not alone. Unlike a standard pill picked up at a corner pharmacy, Tyenne is a specialty biologic — and that category of medication comes with its own set of access hurdles that can feel maddening for patients who need treatment now.

This article breaks down exactly why Tyenne can be difficult to find and access, and what steps you can take to speed up the process.

What Is Tyenne, and Why Is It Considered a Specialty Drug?

Tyenne (tocilizumab-aazg) is a biosimilar to Actemra (tocilizumab), manufactured by Fresenius Kabi. It was FDA-approved on March 5, 2024, making it the first tocilizumab biosimilar available in both intravenous (IV) and subcutaneous (SC) formulations in the United States. It belongs to a class of drugs called interleukin-6 (IL-6) receptor antagonists, which work by blocking a key inflammation-promoting protein in the immune system.

Like all biologic drugs, Tyenne is a large, complex molecule derived from living cells. It cannot be manufactured the same way as a small-molecule generic pill. This complexity means Tyenne is dispensed almost exclusively through specialty pharmacies — not the everyday retail chains most people use for common prescriptions.

Why Can't I Just Pick Up Tyenne at My Local Pharmacy?

Most retail pharmacies — CVS, Walgreens, Rite Aid — are not equipped to handle specialty biologics like Tyenne. These drugs require:

Cold-chain storage (refrigeration between 36°F and 46°F)

Specialized handling and distribution

Insurance benefit verification and prior authorization support

Clinical coordination with prescribers

For the IV formulation, Tyenne is typically administered in a healthcare setting — a clinic, hospital infusion center, or rheumatologist's office — not dispensed through a retail pharmacy at all. The SC formulation can be self-injected at home after training, and is dispensed through specialty pharmacies like Walgreens Specialty Pharmacy, CVS Specialty, or Accredo.

The Prior Authorization Bottleneck

The single biggest reason Tyenne patients face delays is prior authorization (PA). Most insurance plans require PA before they will cover any specialty biologic, including Tyenne. This process involves your doctor's office submitting clinical documentation proving that:

You have a qualifying diagnosis (e.g., moderate-to-severe RA, GCA, PJIA, SJIA)

You have tried and failed other therapies first (step therapy)

Tyenne is the appropriate next step in treatment

According to GoodRx, the insurance approval process for specialty drugs like Tyenne typically takes about 2–4 weeks. That's two to four weeks without your medication while paperwork moves between your doctor's office, your insurance company, and the specialty pharmacy.

Step Therapy: Why You May Have to Try Other Drugs First

Many insurance plans require patients to try and fail one or more TNF inhibitors (like Humira, Enbrel, or their biosimilars) before they will approve an IL-6 inhibitor like Tyenne. This is called step therapy, and it can add months to your treatment journey even when your doctor believes Tyenne is the right drug for you from the start.

Some plans have made Tyenne a preferred biosimilar (Blue Cross Blue Shield of Michigan, for example, named Tyenne as its preferred tocilizumab product effective June 2025), which can simplify coverage. But plan policies vary widely — always check your specific formulary.

Is There a Tyenne Shortage in 2026?

As of 2026, there is no active FDA shortage of Tyenne. The drug launched in April 2024 (IV formulation) and July 2024 (SC formulation) and has been steadily available through specialty pharmacy channels. The access challenges patients face are not typically due to supply problems — they stem from the prior authorization process, specialty pharmacy routing, and insurance benefit design.

However, if your specialty pharmacy is out of stock or is experiencing a delay, you do have options. Your prescriber can work with an alternative specialty pharmacy, or the manufacturer's support program — KabiCare — can help navigate access issues.

How the KabiCare Program Can Help

Fresenius Kabi offers the KabiCare patient support program for Tyenne patients. Through KabiCare, patients can receive help with:

Insurance coverage verification and prior authorization support

Copay assistance (eligible commercially insured patients may pay as little as $0)

Injection training and disease education

Refill reminders and ongoing treatment support

Contact KabiCare at 1-833-522-4227 or visit kabicare.us to enroll. If you are uninsured or underinsured, a patient assistance program is also available through the same number.

What to Do If You Can't Access Tyenne Right Now

Here are steps to take if you're having trouble accessing your Tyenne prescription:

Call your doctor's office to confirm they submitted all PA documentation. Ask for the PA status.

Contact your insurance plan directly to check the PA status and expected approval timeline.

Enroll in KabiCare (1-833-522-4227) — they can help navigate insurance issues on your behalf.

Ask your specialty pharmacy if there are any stock or fulfillment delays and request an ETA.

If a specific pharmacy is delayed, ask your doctor if they can route the prescription to an alternate in-network specialty pharmacy.

medfinder Can Help You Find Tyenne Near You

If you're struggling to find Tyenne through your current pharmacy, medfinder can help. medfinder contacts pharmacies near you to check which ones can fill your prescription, so you don't have to spend hours on hold. Just provide your medication, dosage, and location — medfinder does the calling and texts you the results.

For more tips, read our full guide on how to find Tyenne in stock near you.